New shot could zap skin cancer without surgery

NCT ID NCT07670858

Recruiting now Disease control Sponsor: Feldan Therapeutics Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 30, 2026 · Updated 2 times

Summary

This early-phase trial tests an injected drug called FLD-103 for nodular basal cell carcinoma, a common skin cancer. About 48 adults will receive either one or several injections directly into their tumor. The main goal is to check safety and find the right dose, while also seeing if the injection shrinks the cancer.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: FLD-103 (injected into the tumor)
What this could lead to: If it works, this could lead to a new way to treat basal cell skin cancer without surgery.
What could go wrong: This is a very early, small trial (48 people) testing safety first. It may not shrink tumors or could cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NODULAR BASAL CELL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

nodular basal cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NODULAR BASAL CELL CARCINOMA

Contacts and locations

Locations

Equity Medical
RECRUITING

Bowling Green, Kentucky, 42104, United States
Equity Medical
NOT_YET_RECRUITING

New York, New York, 10023, United States
FNQH Cairns Skin Cancer Clinic
RECRUITING

Westcourt, Queensland, 4870, Australia
Innovate Clinical Research
RECRUITING

Waitara, New South Wales, 2077, Australia
Novatrials
RECRUITING

Charlestown, New South Wales, 2290, Australia
Scientia Clinical Research
RECRUITING

Randwick, New South Wales, 2031, Australia
Translational Research Institute
RECRUITING

Woolloongabba, Queensland, 4102, Australia
Veracity Clinical Research
RECRUITING

Woolloongabba, Queensland, 4102, Australia
Woden Dermatology
RECRUITING

Phillip, Australian Capital Territory, 2606, Australia

More trials for these conditions

Other studies related to the condition(s) this trial covers.